RxDoctor Payments Data

John Wickman

Family Practice · Memphis, TNNPI 1871513739

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 46.2% of the total. Reporting peaked in 2021 at $629 and has fallen 72.7% since, to $171 in 2025. Among family practice clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,598in general payments, 2019–2025

Across 64 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$739
  • Merck$127
  • Esperion Therapeutics, Inc.$119
  • Boehringer Ingelheim$101
  • AstraZeneca$96
  • Abbott$90
  • plus $326 from 11 others

What the payments were for

  • Food & beverage$1,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,598 in reported general payments places this provider in the 95th percentile of 184 family practice providers in Tennessee.

See all family practice providers in Tennessee

Medicare billing

Part B allowed, 2024
$22,344
Medicare patients
64
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$47,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$14,963
FarxigaDapagliflozin Propanediol22$12,444
Breo ElliptaFluticasone/Vilanterol18$7,828
VascepaIcosapent Ethyl12$3,881
Atorvastatin Calcium148$1,308
Albuterol Sulfate HfaAlbuterol Sulfate40$1,236
Metformin Hcl ErMetformin Hcl62$1,141
Gabapentin40$679
Valsartan13$669
Irbesartan32$630
Losartan Potassium46$579
Omeprazole67$526
Escitalopram Oxalate36$438
Montelukast Sodium23$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$47,96334 claims
AstraZenecaFarxiga$96$12,44422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 184 family practice providers in Tennessee.

Other family practice in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →